FDA ad­comms slat­ed to re­view da­ta on long-term opi­oid use, over­dos­es

FDA ad­vi­sors next week will dis­cuss the risks of long-term opi­oid use dur­ing a joint-com­mit­tee meet­ing that will ex­am­ine two com­plet­ed post-mar­ket­ing stud­ies the agency …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER